Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (31)

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

2022

  1. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

    Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210

  2. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

  2. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

    ESMO open, Vol. 6, Núm. 2, pp. 100062

  3. Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

    Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26

2020

  1. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected

    Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116

2019

  1. Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials

    ESMO Open, Vol. 4, Núm. 6

  2. Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts

    Journal of Pain Research, Vol. 12, pp. 2349-2358

2018

  1. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612

  2. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

  3. Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study

    Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 613-618

2017

  1. Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome

    PLoS ONE, Vol. 12, Núm. 11

2016

  1. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

2015

  1. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy

    Molecular Diagnosis and Therapy, Vol. 19, Núm. 6, pp. 397-408

  2. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

    Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541

2014

  1. Assignment of tumor subtype by genomic testing and pathologic-based approximations: Implications on patient's management and therapy selection

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 386-394

2013

  1. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients

    Annals of Oncology, Vol. 24, Núm. 3, pp. 655-661

2012

  1. Glutathione S-transferase P1 c.313a > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients

    Annals of Oncology, Vol. 23, Núm. 7, pp. 1750-1756

  2. Topoisomerase 2 alpha: A real predictor of anthracycline efficacy?

    Clinical and Translational Oncology, Vol. 14, Núm. 3, pp. 163-168